These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 18221057)

  • 21. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
    Johnstone RW
    Nat Rev Drug Discov; 2002 Apr; 1(4):287-99. PubMed ID: 12120280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
    Kim DH; Kim M; Kwon HJ
    J Biochem Mol Biol; 2003 Jan; 36(1):110-9. PubMed ID: 12542981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Assay for inhibitory activity of histone deacetylase].
    Yoshida M
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted histone deacetylase inhibition for cancer therapy.
    Vigushin DM; Coombes RC
    Curr Cancer Drug Targets; 2004 Mar; 4(2):205-18. PubMed ID: 15032670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
    Shankar S; Srivastava RK
    Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone deacetylase inhibitors: gathering pace.
    Carey N; La Thangue NB
    Curr Opin Pharmacol; 2006 Aug; 6(4):369-75. PubMed ID: 16781195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitors open new doors in cancer therapy.
    McLaughlin F; La Thangue NB
    Biochem Pharmacol; 2004 Sep; 68(6):1139-44. PubMed ID: 15313411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylase inhibitors and cancer: from cell biology to the clinic.
    Hess-Stumpp H
    Eur J Cell Biol; 2005 Mar; 84(2-3):109-21. PubMed ID: 15819394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone acetylation and the cell-cycle in cancer.
    Wang C; Fu M; Mani S; Wadler S; Senderowicz AM; Pestell RG
    Front Biosci; 2001 Apr; 6():D610-29. PubMed ID: 11282573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Histone-deacetylases inhibitors: from TSA to SAHA].
    Peixoto P; Lansiaux A
    Bull Cancer; 2006 Jan; 93(1):27-36. PubMed ID: 16455503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylases.
    Marks PA; Miller T; Richon VM
    Curr Opin Pharmacol; 2003 Aug; 3(4):344-51. PubMed ID: 12901942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics?
    Chen JS; Faller DV; Spanjaard RA
    Curr Cancer Drug Targets; 2003 Jun; 3(3):219-36. PubMed ID: 12769690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.
    Li Z; Zhu WG
    Int J Biol Sci; 2014; 10(7):757-70. PubMed ID: 25013383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HDACi--going through the mechanisms.
    Wanczyk M; Roszczenko K; Marcinkiewicz K; Bojarczuk K; Kowara M; Winiarska M
    Front Biosci (Landmark Ed); 2011 Jan; 16(1):340-59. PubMed ID: 21196174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone deacetylase inhibitors: current status and overview of recent clinical trials.
    Ma X; Ezzeldin HH; Diasio RB
    Drugs; 2009 Oct; 69(14):1911-34. PubMed ID: 19747008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.
    Langley B; Gensert JM; Beal MF; Ratan RR
    Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):41-50. PubMed ID: 15723612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
    Kelly WK; Marks PA
    Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.
    Weidle UH; Grossmann A
    Anticancer Res; 2000; 20(3A):1471-85. PubMed ID: 10928059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.